Progenics Awarded $6.0 Million for HIV Therapy and Vaccine Programs - 500 Beiträge pro Seite

[jen]

Nachdem sich auch Progenics dem Downtrend in letzter Zeit nicht ganz entziehen konnte, nun endlich mal wie-
der eine erfreuliche Nachricht, die dem Kurs hoffentlich wieder etwas Auftrieb geben wird:


Progenics Awarded $6.0 Million for HIV Therapy and Vaccine Programs

TARRYTOWN, N.Y., Oct. 17 /PRNewswire/ -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that it had
been awarded approximately $6.0 million from the National Institutes of Health (NIH) for the development of novel therapies and
vaccines for HIV infection. The awards consist of a research grant for $4.0 million, two Phase I Small Business Innovation Research
(SBIR) grants for $1.2 million, and a research contract in the amount of $800,000.

The first award advances Progenics` efforts to develop a safe and effective vaccine against HIV infection. The two-year grant supports
the production and testing of new vaccine candidates in monkeys and other animals. Compared with experimental HIV vaccines
developed to date, the new vaccines more faithfully mimic the active form of the viral envelope glycoproteins gp120 and gp41, which
allow the virus to penetrate and infect host cells. The vaccines exploit recent discoveries by Progenics` scientists and their collaborators
at Weill Medical College of Cornell University (New York City). Additional collaborators on the project include Tulane Regional
Primate Research Center (New Orleans, LA) and AlphaVax, Inc. (Durham, NC).

The first SBIR grant will fund a two-year project to develop cost-effective methods for the manufacture of PRO 542, Progenics` most
clinically advanced HIV therapy. PRO 542 is a novel antibody-like molecule that neutralizes the virus and prevents it from attaching to
and infecting host cells. The project will optimize the production of PRO 542 in the milk of transgenic dairy animals and is a
collaboration with Genzyme Transgenics Corporation, a recognized leader in the field of transgenic technology.

The second SBIR award will fund a two-year project to explore the breadth, potency, and durability of PRO 140 therapy in laboratory
and animal models of HIV infection. PRO 140 is a monoclonal antibody against the CCR5 fusion co-receptor used by the virus to
enter target cells. Entry inhibitors represent a promising new class of HIV therapeutic agents. The project is a collaborative effort
between Progenics, Weill Medical College of Cornell University, and Scripps Research Institute (La Jolla, CA).

The research contract supports a complementary HIV vaccine strategy. The one-year award provides funding for production and
preclinical testing of novel gp120 subunit vaccines that are modified to further improve the production of virus-neutralizing antibodies.

"We are honored to receive these NIH awards," said Paul J. Maddon, M.D., Ph.D., Progenics` Chairman and Chief Executive Officer.
"The HIV programs being pursued by Progenics with its academic and industrial partners are on the leading edge of innovation in the
field and NIH`s continued funding provides much appreciated recognition of the high caliber of our collaborations."

Progenics Pharmaceuticals, Inc. is a biopharmaceutical company focusing on the development and commercialization of products for
the treatment and prevention of cancer, viral, and other life-threatening diseases. The Company`s lead HIV product, PRO 542, has
completed two Phase I/II clinical trials, and two follow-on HIV products, PRO 367 and PRO 140, are preparing to commence Phase
I/II trials. Progenics also has collaborations with F. Hoffmann-La Roche Ltd in the area of HIV fusion co-receptors, and with
American Home Products and Pharmacopeia, Inc. focusing on HIV attachment and fusion. The Company`s most advanced product,
GMK, is a cancer vaccine in pivotal Phase III clinical trials for the treatment of malignant melanoma. A second cancer vaccine, MGV,
with broad application to a variety of cancers, is entering Phase II trials. GMK and MGV are being developed in collaboration with
Bristol-Myers Squibb Company. The Company, with Cytogen Corporation, has formed a joint venture focusing on the development of
cancer immunotherapies based on PSMA (Prostate Specific Membrane Antigen) technology. The Company is also developing a novel
small-molecule antioxidant, DHA, to treat stroke and other disorders.


Gruss,
jen

[jen]

Progenics soeben in Amerika mit 10% im Plus gestartet!

Wollen wir hoffen, dass der heutige Tag den Turnaround am Nasdaq bringt!

Gruss,
jen

[Xedi]

Progenics kratzt an der 200-Linie.
Gibt es was neues

Gruß X

[Xedi]

War leider falsch, es ist die 38-Linie.

Nasdaq 24.62 §/ + 14.53 %

Und nochmals, gibt es was neues.

Gruß X

[DanGurney]

würde mich auch interessieren

momentan 31,25 § / + 17,92 % echt der wahnsinn

[Morsbach]

Progenics Parma bei ca. 34 Euro, gab es Zahlen oder gute Meldungen?
Bei Yahoo steht ein Bericht unter Finanzen, hat denn einer gelesen denn bei mir kommt ständig eine Fehlermeldung und die Seite geht weg. Es geht glaube ich dabei um Zahlen vom 3Quartal, konnte es aber wegen meiner Rechnenprobleme nicht genau durchlesen und weil der Bericht in Englisch geschrieben ist dauert es bei mir eh etwas länger bis ich das durchgelesen habe.
Währe schön wenn jemand etwas darüber Berichten könnte.

[Morsbach]

Progenics Parma bei ca. 34 Euro, gab es Zahlen oder gute Meldungen?
Bei Yahoo steht ein Bericht unter Finanzen, hat denn einer gelesen denn bei mir kommt ständig eine Fehlermeldung und die Seite geht weg. Es geht glaube ich dabei um Zahlen vom 3Quartal, konnte es aber wegen meiner Rechnenprobleme nicht genau durchlesen und weil der Bericht in Englisch geschrieben ist dauert es bei mir eh etwas länger bis ich das durchgelesen habe.
Währe schön wenn jemand etwas darüber Berichten könnte.